Citation: Surgical Oncology. 27(4):657-662, 2018 Dec..Journal: Surgical oncology.Published: ; 2018ISSN: 0960-7404.Full author list: Liberale G; Sugarbaker PH.UI/PMID: 30449489.Subject(s): Adult | Aged | *Cytoreduction Surgical Procedures/ae [Adverse Effects] | Female | Humans | Male | Middle Aged | *Peritoneal Neoplasms/co [Complications] | Peritoneal Neoplasms/sc [Secondary] | *Peritoneal Neoplasms/su [Surgery] | *Peritonitis/et [Etiology] | *Peritonitis/pa [Pathology] | PrognosisInstitution(s): Washington Cancer InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access onlineDigital Object Identifier: https://dx.doi.org/10.1016/j.suronc.2018.08.005 (Click here)Abbreviated citation: Surg Oncol. 27(4):657-662, 2018 Dec.Abstract: Sclerosing encapsulating peritonitis (SEP) is a rare entity characterized by encapsulation of the small bowel and/or the colon by a fibrous tissue that forms a shell. Intraperitoneal chemotherapy (IPC) has been reported to be a potential causative factor of secondary SEP. However, few studies have reported on secondary SEP related to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Here, we review results from four clinical cases of SEP associated with CRS and HIPEC. In all four patients, additional surgery was necessary to alleviate recurrent episodes of small bowel obstruction. These obstructions can occur as early as several weeks after CRS plus HIPEC or as late as 3 years after treatment. Of utmost importance is the prevention of fistulization which can result in enteric contamination of the peritoneal space. To date, no solution to SEP has been identified except additional surgery but it is evident that these reoperative experiences are difficult for both surgeon and patient. The etiopathogenesis of SEP in this setting remains unknown but it is clear that it is related to chronic inflammation of the peritoneum. Large studies are needed to identify the incidence and potential common causes of SEP after CRS and HIPEC.Abstract: Copyright (c) 2018 Elsevier Ltd. All rights reserved.